S. Boyd

Oncogenic B-RAFV600E signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion

G. Mann, G. Pupo, R. Scolyer, 2012, The Journal of investigative dermatology.

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

P. Hersey, H. Tseng, K. H. Tay, 2014, The Journal of investigative dermatology.

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

G. Pupo, R. Scolyer, L. Haydu, 2014, Clinical Cancer Research.

Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, 2014, Clinical Cancer Research.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Johnny Lo, Varsha Tembe, Melanie Ziman, 2015, Oncotarget.

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

T M Becker, S C Boyd, B Mijatov, 2014, Oncogene.

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

R. Kefford, H. Rizos, Suzanah C. Boyd, 2018, Oncogenesis.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

N. Hayward, G. Pupo, P. Johansson, 2017, Biomarker Research.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

G. Mann, R. Scolyer, V. Jakrot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

James B. Freeman, R. Scolyer, M. Millward, 2015, Oncotarget.